Merck Millipore to Introduce New Processing Technologies at BPI Conference
Merck Millipore, the life science division of Merck, will be showcasing its new biopharmaceutical processing solutions at the BioProcess International Conference & Exhibition 20–23 October in Boston. These products add to Merck Millipore's complete range of upstream and downstream products, helping to improve manufacturing productivity and accelerate time-to-market.
The new technologies on display at the BioProcess International Conference & Exhibition will include
PureFlex Plus Single-Use Process Container Film
Merck Millipore is introducing PureFlex Plus film, a robust, durable film used in the construction of Mobius single-use process containers for biopharmaceutical manufacturing. The film's rugged outer layer offers strong resistance to leak formation, making it ideal for the demanding applications often encountered in large volume operations.
The PureFlex Plus film can be used throughout the entire manufacturing process. It builds upon Merck Millipore's established PureFlex film technology by adding a new, more robust linear low density polyethlene (LLDPE) outer layer to reduce susceptibility to leaks through abrasion, puncture, stretching and tearing.
Cellvento CHO Cell Culture Media
Merck Millipore is expanding its Cellvento CHO cell culture media portfolio of chemically defined, non-animal origin media formulations for batch and fed-batch mode operations. Three new products are launching to specifically address DHFR negative cell lines: Cellvento CHO-110 medium, Cellvento CHO-210 medium and Cellvento Feed-210 media.
Cellvento CHO-110 medium is recommended for batch application and seed train expansion as its rich formulation supports high cell growth. Cellvento CHO-210 medium and its companion feeds are effective at achieving high-density cell growth and competitive productivity with DHFR negative CHO suspension cell types and expression systems, especially recombinant CHO DG44 cell lines.
NovaSeptum Single-Use Holders
NovaSeptum single-use holders are a new component of Merck Millipore's NovaSeptum fully disposable sampling systems, which help prevent contamination when sampling fluids from aseptic and sterile processes. The new single-use holders are compatible with NovaSeptum containers, helping reduce validation requirements, and can be filled with any type of container using a 2-mm trigger.
Ready-to-use, flexible and fully validated, the single-use holders are ideal for manufacturers dealing with recombinant proteins, vaccines and mAbs who need to autoclave before starting their processes.
Chromabolt Chromatography Resins
Merck Millipore is announcing the availability of three new chromatography resins for its Chromabolt prepacked columns. These pre-validated chromatography columns can come packed with either strong cation exchangers, weak cation exchangers or strong anion exchangers, freeing up end users' time and resources by eliminating manual column packing and cleaning.
Chromabolt columns are available in three sizes — 10 cm, 20 cm and 32 cm inner diameter (i.d.) — and are designed for pilot and early clinical manufacturing. The three new resins are Fractogel EMD SE Hicap, Fractogel EMD COO(M), and Eshmuno Q.
Merck Millipore will also be presenting at the BioProcess International Conference & Exhibition:
Integrated Single-Use Purification Technologies Enabling Continuous MAb Processing
Presented by Michael W. Phillips
Director, Technology Development, Merck Millipore
Tuesday, 21 October,12:00 p.m.
The Development of a More Physically Robust Single-Use Fluid Management Film for Demanding Bioprocess Applications
Presented by Michael Felo, Group Product Manager, Single Use, Merck Millipore
Wednesday, 22 October, 1:15 p.m.–1:35 p.m.
BioProcess International Theater
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...